Dolecek R, Janstová V
Pharmatherapeutica. 1985;4(2):81-7.
Eight underweight children, 3 of them with anorexia nervosa, were treated for 3 months without interruption with 1.0 to 1.5 mg pizotifen per day. Their mean weight gain was 4.6 +/- 1.1 kg (range 2.5 to 11.5 kg) and their height increased by 1.4 +/- 0.5 cm (range 0 to 4 cm), as in normal controls. Before the start of and at the end of treatment with pizotifen, protracted insulin tolerance tests were performed, during which blood glucose and growth hormone (hGH) levels were measured (10 times over 2 hours). In the same patients, hGH levels were measured (6 times over 2 hours) in the late evening, during sleep. Treatment with pizotifen did not decrease the hGH response to insulin-caused hypoglycaemia. After pizotifen, some blood glucose levels were lower than before pizotifen. The mean hGH values during sleep did not change significantly after pizotifen. In 1 patient with anorexia nervosa the increased hGH levels decreased during treatment to very low levels (she gained 11.5 kg); in another patient they increased (she gained 2.5 kg). The possible mechanisms of pizotifen action are discussed briefly. There were no changes in serum prolactin levels during pizotifen administration.
八名体重过轻的儿童，其中3名患有神经性厌食症，每天服用1.0至1.5毫克苯噻啶，连续治疗3个月无间断。他们的平均体重增加了4.6±1.1千克（范围为2.5至11.5千克），身高增加了1.4±0.5厘米（范围为0至4厘米），与正常对照组情况相同。在开始使用苯噻啶治疗前及治疗结束时，进行了延长胰岛素耐量试验，在此期间测量血糖和生长激素（hGH）水平（2小时内测量10次）。在同一批患者中，于深夜睡眠期间测量hGH水平（2小时内测量6次）。苯噻啶治疗并未降低hGH对胰岛素引起的低血糖的反应。使用苯噻啶后，一些血糖水平低于使用苯噻啶前。睡眠期间的平均hGH值在使用苯噻啶后无显著变化。在1名神经性厌食症患者中，治疗期间升高的hGH水平降至非常低的水平（她体重增加了11.5千克）；在另1名患者中hGH水平升高（她体重增加了2.5千克）。简要讨论了苯噻啶作用的可能机制。服用苯噻啶期间血清催乳素水平无变化。
